UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This study is designed for exploring the preliminary safety and efficacy of the recombinant
allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with
CD19-positive B cell hematolymphatic malignancies.